CVRx (CVRX) Expected to Announce Earnings on Thursday

CVRx (NASDAQ:CVRX) is anticipated to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.49) per share and revenue of $13.93 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

CVRx (NASDAQ:CVRX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.01). The company had revenue of $15.71 million during the quarter, compared to analyst estimates of $15.55 million. CVRx had a negative net margin of 84.93% and a negative return on equity of 152.35%. On average, analysts expect CVRx to post ($2.00) EPS for the current fiscal year and ($1.91) EPS for the next fiscal year.

CVRx Price Performance

NASDAQ CVRX opened at $1.37 on Tuesday. The stock’s 50-day moving average price is $2.23 and its two-hundred day moving average price is $5.24. The company has a current ratio of 8.04, a quick ratio of 6.87 and a debt-to-equity ratio of 2.94. The company has a market cap of $36.50 million, a PE ratio of -0.69 and a beta of 0.77. CVRx has a 1 year low of $1.25 and a 1 year high of $11.30.

Wall Street Analysts Forecast Growth

CVRX has been the subject of several recent analyst reports. Canaccord Genuity Group set a $5.00 target price on shares of CVRx in a report on Tuesday, September 22nd. Craig Hallum downgraded shares of CVRx from a “buy” rating to a “hold” rating and set a $4.00 target price on the stock. in a research report on Friday, August 7th. Weiss Ratings restated a “sell (e+)” rating on shares of CVRx in a report on Friday. Wall Street Zen upgraded shares of CVRx from a “sell” rating to a “hold” rating in a research report on Saturday, October 10th. Finally, Piper Sandler downgraded shares of CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price target for the company. in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, CVRx has an average rating of “Hold” and a consensus target price of $4.30.

Insider Buying and Selling

In other CVRx news, COO Brent Binkowski bought 26,223 shares of the stock in a transaction on Thursday, August 13th. The shares were bought at an average price of $2.91 per share, with a total value of $76,308.93. Following the purchase, the chief operating officer directly owned 56,514 shares in the company, valued at $164,455.74. The trade was a 86.57% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 16.60% of the company’s stock.

CVRx Company Profile

CVRx, Inc (NASDAQ: CVRX) is a medical device company focused on developing and commercializing neuromodulation therapies for patients with cardiovascular diseases. The company’s technology is designed to activate the body’s natural nervous system pathways to help regulate cardiovascular function.

CVRx’s primary product is the Barostim system, an implantable device that delivers electrical stimulation to baroreceptors located near the carotid arteries. By influencing signals between the cardiovascular system and the brain, Barostim is intended to reduce excessive sympathetic nervous system activity and improve symptoms and function in certain patients with heart failure.